Home » Stocks » AGEN

Agenus Inc. (AGEN)

Stock Price: $5.19 USD -0.07 (-1.33%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $5.11 -0.08 (-1.54%) Jul 29, 7:54 PM
Market Cap 1.15B
Revenue (ttm) 84.76M
Net Income (ttm) -190.13M
Shares Out 200.33M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $5.19
Previous Close $5.26
Change ($) -0.07
Change (%) -1.33%
Day's Open 5.29
Day's Range 5.15 - 5.37
Day's Volume 1,613,084
52-Week Range 2.50 - 5.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

A top company executive is stepping down in the very near future.

2 days ago - The Motley Fool

Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET

3 days ago - GlobeNewsWire

Agenus (AGEN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Re...

3 days ago - Zacks Investment Research

VACAVILLE, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. has purchased 120-acres in Vacaville's California Biomanufacturing Center from housing developer A.G. Spanos, a transaction that represen...

2 weeks ago - GlobeNewsWire

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...

3 weeks ago - GlobeNewsWire

LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adju...

3 weeks ago - GlobeNewsWire

Agenus (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

3 weeks ago - Zacks Investment Research

Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our short...

3 weeks ago - Zacks Investment Research

LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...

1 month ago - GlobeNewsWire

The biotech took a major step toward becoming a commercial-stage cancer company.

1 month ago - The Motley Fool

The FDA has accepted for review Agenus Inc's (NASDAQ: AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer with disease progression on or after chemot...

1 month ago - Benzinga

LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adju...

1 month ago - GlobeNewsWire

Meme penny stocks are heating up; are these 3 on your watchlist? The post Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other stocks mentioned: CYCN, MOSY
1 month ago - PennyStocks

There was some positive news, but it probably wasn't a huge catalyst for the stock.

1 month ago - The Motley Fool

LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...

1 month ago - GlobeNewsWire

LEXINGTON, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...

1 month ago - GlobeNewsWire

Find out what pushed them up to see if the good times can keep rolling.

Other stocks mentioned: ALPN, ANVS
2 months ago - The Motley Fool

LEXINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed...

2 months ago - GlobeNewsWire

Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, New...

Other stocks mentioned: ACST, ADXS
2 months ago - PennyStocks

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Other stocks mentioned: BMY
2 months ago - Zacks Investment Research

Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt.

Other stocks mentioned: AUPH
2 months ago - The Motley Fool

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

Other stocks mentioned: BMY
2 months ago - Zacks Investment Research

The biotech announced a big licensing deal with Bristol Myers Squibb.

2 months ago - The Motley Fool

Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News an...

Other stocks mentioned: ACRX, ONTX
2 months ago - PennyStocks

Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGEN1777 ...

Other stocks mentioned: BMY
2 months ago - Benzinga

Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET

2 months ago - GlobeNewsWire

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments

2 months ago - GlobeNewsWire

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...

Other stocks mentioned: ATOS, CDMO, COCP, OCGN, SIGA, SIOX
2 months ago - InvestorPlace

The company announced mixed Q1 results on a day when many biotech stocks were sinking.

2 months ago - The Motley Fool

Agenus (AGEN) delivered earnings and revenue surprises of 12.90% and -46.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines des...

2 months ago - GlobeNewsWire

LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design...

3 months ago - GlobeNewsWire

Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET

3 months ago - GlobeNewsWire

LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adj...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design...

3 months ago - GlobeNewsWire

Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Agenus (NASDAQ:AGEN) moved higher by 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 9.09% year over year to ($0.20), which beat ...

4 months ago - Benzinga

LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines ...

4 months ago - GlobeNewsWire

LEXINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d...

4 months ago - GlobeNewsWire

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

Agenus Inc (NASDAQ: AGEN) has announced positive preliminary results from its Phase 1 trial evaluating its iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidia...

5 months ago - Benzinga

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

6 months ago - GlobeNewsWire

Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

8 months ago - GlobeNewsWire

About AGEN

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company als... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2000
CEO
Garo Armen
Employees
359
Stock Exchange
NASDAQ
Ticker Symbol
AGEN
Full Company Profile

Financial Performance

In 2020, Agenus's revenue was $88.17 million, a decrease of -41.24% compared to the previous year's $150.05 million. Losses were -$180.91 million, 68.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Agenus stock is "Strong Buy." The 12-month stock price forecast is 9.00, which is an increase of 73.41% from the latest price.

Price Target
$9.00
(73.41% upside)
Analyst Consensus: Strong Buy